Capital eventCH·2d ago✦ enriched
NeuroGyn AG closes CHF 4 million Series A to advance pelvic neuromodulation - Neurogyn
NeuroGyn AG raised CHF 4 million in a Series A led by a Swiss medical-technology investor, earmarked to fund initial human trials, regulatory advancement, and commercial development of its PosStim™ pelvic neuromodulation platform.
WARM· 56intent / 100
▸ why this score▾ score breakdown
- default: P(contract_to_capital_90d) · p=0.40 × w=3.0+1.2
- default: OON discount · × 0.75-0.5
- Final score (ambiguity-dampened) · default=56+56
- V2 winner: default · default=56+0